← All trials
NCT04965389
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2021
- Primary completion
- Aug 22, 2021
- Completion date
- Oct 1, 2021
- First posted
- Jul 16, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 17
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.